Targeted therapy with kinase inhibitors in aggressive endocrine tumors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy with kinase inhibitors in aggressive endocrine tumors
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 9, Pages 1187-1203
Publisher
Informa Healthcare
Online
2013-05-16
DOI
10.1517/14656566.2013.796931
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
- (2017) S. I. Sherman et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide in aggressive pituitary adenomas and carcinomas
- (2012) LD Ortiz et al. Clinics
- Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
- (2012) M. Daimon et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A High Percentage ofBRAFV600EAlleles in Papillary Thyroid Carcinoma Predicts a Poorer Outcome
- (2012) Anna Guerra et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Diagnosis and management of parathyroid cancer
- (2012) Klaus-Martin Schulte et al. Nature Reviews Endocrinology
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Status and Perspectives of Targeted Therapy in Well-Differentiated Neuroendocrine Tumors
- (2012) Boris G. Naraev et al. ONCOLOGY
- Genetic controls and cellular behaviors in branching morphogenesis of the renal collecting system
- (2012) Frank Costantini Wiley Interdisciplinary Reviews-Developmental Biology
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer
- (2011) Tae Hyuk Kim et al. CANCER
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
- (2011) Maralyn Druce et al. CLINICAL ENDOCRINOLOGY
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
- (2011) Alfredo Berruti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Everolimus is an active agent in medullary thyroid cancer: a clinical andin vitrostudy
- (2011) A. Faggiano et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas
- (2011) Margarida M. Moura et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model
- (2011) Beate Schultheis et al. LEUKEMIA RESEARCH
- Molecular genetics and diagnosis of thyroid cancer
- (2011) Yuri E. Nikiforov et al. Nature Reviews Endocrinology
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current and Emerging Therapies for Advanced Adrenocortical Carcinoma
- (2011) L. J. Tacon et al. ONCOLOGIST
- Bronchial Fistula Associated with Sunitinib in a Patient Previously Treated with Radiation Therapy
- (2010) Damien Basille et al. ANNALS OF PHARMACOTHERAPY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies
- (2010) Robert T. Jensen et al. CANCER
- Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice
- (2010) Manuela Schmidinger et al. CANCER INVESTIGATION
- Regulation of Insulin-like Growth Factor–Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors
- (2010) Mabrouka Doghman et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- Sustained Remission with the Kinase Inhibitor Sorafenib in Stage IV Metastatic Adrenocortical Carcinoma
- (2010) Charles Butler et al. Endocrine Practice
- Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung
- (2010) Luisella Righi et al. ENDOCRINE-RELATED CANCER
- Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma
- (2010) Gregory S Y Ong et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Bruce G. Robinson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
- (2010) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Role of the mTOR Pathway in Normal and Tumoral Adrenal Cells
- (2010) M.C. De Martino et al. NEUROENDOCRINOLOGY
- Thyroid Cancer Incidence and Survival in the National Cancer Institute Surveillance, Epidemiology, and End Results Race/Ethnicity Groups
- (2010) Guo-Pei Yu et al. THYROID
- Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
- (2010) Nicole M Agostino et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
- (2009) Takashi Shida et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
- (2009) D. S. Hong et al. CLINICAL CANCER RESEARCH
- E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
- (2009) K. Ikuta et al. CLINICAL CANCER RESEARCH
- Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
- (2009) D Dworakowska et al. ENDOCRINE-RELATED CANCER
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
- (2009) M. R. Druce et al. HORMONE AND METABOLIC RESEARCH
- Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction?
- (2009) O. Bilgir et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma
- (2009) K.-S. Park et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report
- (2009) Jeong-Ok Lee et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Successful Control of Intractable Hypoglycemia Using Rapamycin in an 86-Year-Old Man with a Pancreatic Insulin-Secreting Islet Cell Tumor and Metastases
- (2009) Matthew E. Bourcier et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer
- (2009) Mingzhao Xing et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
- (2009) Maurizio Zangari et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival
- (2009) Aurélien de Reyniès et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
- (2009) Youjin Je et al. LANCET ONCOLOGY
- Glycemic Control in Patients with Insulinoma Treated with Everolimus
- (2009) Matthew H. Kulke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib
- (2009) Kaja Zimmermann et al. ONCOLOGY
- New targets and therapeutic approaches for endocrine malignancies☆
- (2009) Martin Fassnacht et al. PHARMACOLOGY & THERAPEUTICS
- Protein kinase inhibitors: contributions from structure to clinical compounds
- (2009) Louise N. Johnson QUARTERLY REVIEWS OF BIOPHYSICS
- Skin toxicities associated with epidermal growth factor receptor inhibitors
- (2009) Tianhong Li et al. Targeted Oncology
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- (2009) David S. Cooper et al. THYROID
- Hemostatic complications of angiogenesis inhibitors in cancer patients
- (2008) Francesca Elice et al. AMERICAN JOURNAL OF HEMATOLOGY
- Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine
- (2008) Hui Huang et al. CANCER
- The role of mTOR in the management of solid tumors: An overview
- (2008) Alex S. Strimpakos et al. CANCER TREATMENT REVIEWS
- Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
- (2008) Robert C Smallridge et al. ENDOCRINE-RELATED CANCER
- BRAFV600EMutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study
- (2008) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
- (2008) Anthony M. Joshua et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors
- (2008) Camilo Jimenez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma
- (2008) Ferdous M. Barlaskar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib
- (2008) Natascha A.J.B. Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
- (2008) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate
- (2008) Noah M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- The EGFR Is Required for Proper Innervation to the Skin
- (2008) Adel Maklad et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
- Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
- (2008) M. Breccia et al. LEUKEMIA RESEARCH
- Primary Ovarian Insufficiency Associated with Imatinib Therapy
- (2008) Constantinos Christopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of aggressive pituitary adenomas: current treatment strategies
- (2008) Michael Buchfelder Pituitary
- Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics
- (2007) Lisa A. Hammond-Thelin DERMATOLOGIC CLINICS
- Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
- (2007) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)
- (2007) Apostolos Tsapas et al. LEUKEMIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started